Fidanacogene elaparvovec

伊哌非可基

Report date: 2025/03/11 13:53:58

Base Information

Drug NameFidanacogene elaparvovec
Drug Alias NameSPK-FIXAAV8 factor IX gene therapyrAAV-Spark100-hFIX-PaduaFidanacogene elaparvovecfidanacogene elaparvovec-dzkt +[10] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionBlood coagulation pathway activationCoagulation factor IX modulatorsFactor IX gene transference
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia BHemophilia A
Global Approved IndicationsHemophilia B
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCanada
Original Approved Date2024/01/03
Country/TerritoryBelgiumCanadaUnited States +[18] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesChildrens Hospital of Philadelphia
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesChildrens Hospital of PhiladelphiaSpark Therapeutics IncPfizer Europe Ma Eeig
Active IndicationsHemophilia BHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG